DAYTON, Ohio, Oct. 13, 2020 /PRNewswire/ -- Soin
Neuroscience Inc. (SNI), a biotech startup based in Dayton, Ohio, has developed a novel
implantable sacral nerve stimulator to treat bladder incontinence.
As many as 46 million Americans 40 years of age or
older have reported symptoms of urinary incontinence often due
to a condition known as overactive bladder, according to the
American Urological Association.
Soin Neuroscience has developed an implantable device where
small electrical leads are placed in an area of nerves in the
sacral foramen that deliver SNIs new proprietary algorithm and may
improve symptoms. This technique is known in medical device circles
as "Sacral Neuromodulation."
"SNI's new sacral nerve stimulation platform is unlike anything
currently available in the market and I think has several
advantages over current technology. I look forward to proving and
testing our approach in an upcoming human study. Our platform is
not used by any currently marketed neuromodulation devices and
quite frankly, the current systems are not capable of replicating
the SNI approach," said coinventor Dr. Amol
Soin, who is also the founder and CEO of Soin
Neuroscience.
The sacral neuromodulation market is expected to reach
$3.15 billion by 2026 and market
share leader Medtronic as well as
newcomer Axonics Modulation have
marketed products. "We believe our technology is distinct and
different, while having several significant advantages compared to
current technology. We look forward to demonstrating those
advantages in studies," Soin noted.
Dr. Amol Soin also noted that
Soin Neuroscience recently received Institutional Review Board (IRB) approval
and will be conducting human trials imminently.
About Soin Neuroscience: Soin Neuroscience Inc. (SNI) is a
biotech company based in Dayton, OH. SNI was founded by
Dr Amol Soin, MD, and has a portfolio of pharmacological
agents to treat various diseases mostly concentrated in non-opioid
based pain management therapies. Recently, SNI started a medical
device division and has several neuromodulation technologies in
development. SNI is also working on machine learning and AI based
technologies to help augment physician decision making to make
precision medicine possible. Our sacral nerve stimulation device is
not approved for use in humans and is currently in early testing
phases. As a result, there are no guarantees or claims of efficacy
and further testing is required. Email Amol
Soin at drsoin@soinneuroscience.com.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/soin-neuroscience-develops-novel-sacral-nerve-stimulator-to-treat-bladder-incontinence-301151364.html
SOURCE Soin Neuroscience